Clinical trial
Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not…
NCT00079183 · Fred Hutchinson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00079183 |
|---|---|
| Title | Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment |
| Official title | A Phase II Clinical Trial to Evaluate the Safety and Efficacy of Sirolimus for Secondary Treatment of Chronic Graft-versus-Host Disease |
| Lead sponsor | Fred Hutchinson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Graft Versus Host Disease |
| Intervention type | Drug |
| Interventions | sirolimus |
| Enrollment | 44 |
| Start date | Apr 1, 2002 |
| Primary completion | Jul 1, 2009 |
| Completion | Jun 10, 2010 |
| First posted | Mar 10, 2004 |
| Last update posted | Jun 20, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: